Hefen Yu
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
Papers in
-
- RNA modifications and cancer 10
- Cancer-related gene regulation 8
- Epigenetics and DNA Methylation 7
- RNA Research and Splicing 6
- Wnt/β-catenin signaling in development and cancer 3
-
- Ferroptosis and cancer prognosis 3
- Co-authors
- Xu Teng (20 shared papers)Wen G. Jiang (13 shared papers)Tianshu Yang (11 shared papers)Yan Wang (13 shared papers)Wei Huang (13 shared papers)Huishan Zhao (6 shared papers)Si Yang (5 shared papers)Xin Yin (9 shared papers)
- Journals
- Frontiers in Oncology (5 papers)International Journal of Oncology (3 papers)Cell Death and Differentiation (2 papers)Oncotarget (2 papers)Frontiers in Pharmacology (2 papers)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Hefen Yu
43 papers receiving 764 citations
Peers
Comparison fields: 5 of 84
- Cancer Research 168
- Molecular Biology 444
- Oncology 113
- Immunology and Allergy 20
- Pulmonary and Respiratory Medicine 93
Countries citing papers authored by Hefen Yu
This map shows the geographic impact of Hefen Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hefen Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hefen Yu more than expected).
Fields of papers citing papers by Hefen Yu
This network shows the impact of papers produced by Hefen Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hefen Yu. The network helps show where Hefen Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Hefen Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 64 | |
| 2 | 2017 | 59 | |
| 3 | 2014 | 51 | |
| 4 | 2018 | 51 | |
| 5 | 2022 | 50 | |
| 6 | 2021 | 47 | |
| 7 | 2020 | 31 | |
| 8 | 2019 | 30 | |
| 9 | 2010 | 29 | |
| 10 | 2020 | 27 | |
| 11 | 2016 | 26 | |
| 12 | 2019 | 22 | |
| 13 | 2023 | 19 | |
| 14 | 2010 | 18 | |
| 15 | The Clinical Implications of RSK1-3 in Human Breast Cancer. | 2016 | 17 |
| 16 | 2018 | 17 | |
| 17 | 2018 | 17 | |
| 18 | 2016 | 16 | |
| 19 | 2024 | 15 | |
| 20 | 2023 | 15 |
About Hefen Yu
Hefen Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Cancer Research and Immunology and Allergy, having authored 44 papers that have together received 774 indexed citations. Recurring topics across this work include RNA modifications and cancer (10 papers), Cancer-related gene regulation (8 papers), Epigenetics and DNA Methylation (7 papers), RNA Research and Splicing (6 papers), Cell Adhesion Molecules Research (5 papers), Ferroptosis and cancer prognosis (3 papers), Cancer Cells and Metastasis (3 papers) and Wnt/β-catenin signaling in development and cancer (3 papers). The work is most often cited by research in Cancer Research (168 citations), Molecular Biology (444 citations), Oncology (113 citations), Immunology and Allergy (20 citations) and Pulmonary and Respiratory Medicine (93 citations). Hefen Yu has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Xu Teng, Wen G. Jiang, Tianshu Yang, Yan Wang, Wei Huang, Huishan Zhao, Si Yang, Xin Yin, Wei Liu and Miaomiao Huo. Their work appears in journals such as Frontiers in Oncology, International Journal of Oncology, Cell Death and Differentiation, Oncotarget and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.